Demant AS is a Denmark-based company engaged in the healthcare industry... Show more
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where WILLF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on WILLF as a result. In of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for WILLF turned negative on June 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for WILLF moved above the 200-day moving average on June 26, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In of 191 cases where WILLF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. WILLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.803) is normal, around the industry mean (24.463). P/E Ratio (25.840) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (1.588) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.982) is also within normal values, averaging (43.062).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry MedicalSpecialties
A.I.dvisor tells us that WILLF and MEDP have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that WILLF and MEDP's prices will move in lockstep.
Ticker / NAME | Correlation To WILLF | 1D Price Change % | ||
---|---|---|---|---|
WILLF | 100% | N/A | ||
MEDP - WILLF | 24% Poorly correlated | +1.55% | ||
CLPBY - WILLF | 23% Poorly correlated | +0.74% | ||
VERO - WILLF | 23% Poorly correlated | +12.60% | ||
ICLR - WILLF | 20% Poorly correlated | +1.30% | ||
WILYY - WILLF | 14% Poorly correlated | N/A | ||
More |